- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01641913
Intestinal Permeability in Response to Treatment in Eosinophilic Esophagitis Patients
Determination of Intestinal Permeability and Response to Treatment in Patients With Eosinophilic Esophagitis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Eosinophilic esophagitis is an allergy mediated disease in which antigens exposed to the gastrointestinal tract trigger a combined immediate hypersensitivity.
The investigators anticipate that patients with active eosinophilic esophagitis will have increased intestinal permeability on urine collection of sugars. The investigators are not sure whether these findings will be found in patients who have been successfully treated with topical esophageal steroids. Improvement in intestinal permeability would be perceived as indicating that esophageal disease drives the intestinal permeability. Lack of improvement would indicate that eosinophilic esophagitis is a more systemic disease in which increased small bowel permeability is a marker or perhaps important driver of the disease.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects between the ages of 18 and 80 with Eosinophilic Esophagitis diagnosed by compatible symptoms, endoscopic findings, histology and lack of response to proton pump inhibitors or negative pH study.
Exclusion:
- Vulnerable populations, such as those with diminished mental acuity, will be excluded.
- Patients allergic to Lactulose
- Women who are pregnant or lactating.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Absorbable sugars
Lactulose (1,000 mg) and mannitol (200 mg).
For the liquid formulation, these sugars will be administered in 250 ml of water.
After oral ingestion of the sugars in liquid form, urine will be collected every 30 minutes for the first 2 hours.
|
Lactulose (1,000 mg) and mannitol (200 mg).
For the liquid formulation, these sugars will be administered in 250 ml of water.
After oral ingestion of the sugars in liquid form, urine will be collected every 30 minutes for the first 2 hours.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess patients gastrointestinal symptoms in patients with EoE by means of standard validated questionnaires
Time Frame: 30 days
|
heartburn, trouble swallowing
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine if patients with eosinophilic esophagitis have increased small intestinal permeability and if this changes in response to topically administered esophageal steroids.
Time Frame: 2 hours
|
2 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David Katzka, MD, Mayo Clinic, Rochester, MN
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12-001344
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eosinophilic Esophagitis
-
Children's Hospital Medical Center, CincinnatiNational Institute of Allergy and Infectious Diseases (NIAID); National Institute... and other collaboratorsCompletedEosinophilic Esophagitis (EoE) | Eosinophilic Gastrointestinal Disorders (EGIDs)United States
-
Federico II UniversityRecruitingEsophagitis, EosinophilicItaly
-
Ann & Robert H Lurie Children's Hospital of ChicagoRecruitingEosinophilic Gastroenteritis | Eosinophilic Esophagitis | Eosinophilic Colitis | Eosinophilic Gastrointestinal DiseaseUnited States
-
Medical University of GrazRecruiting
-
AQILION ABCompletedEosinophilic Esophagitis (EoE)United Kingdom
-
Regeneron PharmaceuticalsSanofiActive, not recruitingEosinophilic Esophagitis (EoE)United States, Canada
-
ShireTakeda Development Center Americas, Inc.TerminatedEosinophilic Esophagitis (EoE)United States
-
ShireCompletedEosinophilic Esophagitis (EoE)United States
-
ShireCompleted
-
ShireCompletedEosinophilic Esophagitis (EoE)United States
Clinical Trials on Absorbable sugars
-
John SievenpiperCanadian Institutes of Health Research (CIHR); The Physicians' Services Incorporated...UnknownCardiovascular Diseases | Obesity | Diabetes Mellitus | Overweight | Metabolic Syndrome | Prediabetic State | Chronic DiseaseCanada
-
The Affiliated Hospital of Qingdao UniversityRecruitingSuture, ComplicationChina
-
University of CatanzaroUnknownPeripheral Vascular Disease
-
Pediatric Clinical Research PlatformRecruitingWounds and InjuriesSwitzerland
-
Ain Shams UniversityCompleted
-
Cambridge GlycoscienceCompletedGastrointestinal ToleranceIreland
-
Johns Hopkins UniversityTerminated
-
University Hospital, Basel, SwitzerlandCompleted
-
University of Texas at AustinUnknownGanglion Cysts | Carpal Tunnel Syndrome | Trigger Finger | Dupuytren Contracture | All Minor Hand Surgery Including | De Quervain SyndromeUnited States
-
Wake Forest University Health SciencesRecruiting